专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US06800455B2 Secreted factors 有权
标题翻译：分散因素
公开(公告)号：US06800455B2
公开(公告)日：2004-10-05
申请号：US09809545
申请日：2001-03-14
申请人： Lawrence W. Stanton , R. Tyler White
发明人： Lawrence W. Stanton , R. Tyler White
IPC分类号： C12P2106
CPC分类号： C07K14/47
摘要： The invention concerns new secreted factors encoded by clones P00184_D11 (SEQ ID NO:1), P00185_D11 (SEQ ID NO:3), P00188_D12 (SEQ ID NO:5), P00188_E01 (SEQ ID NO:7), P00194_G01 (SEQ ID NO:9), P00194_G05 (SEQ ID NO:11), P00194_H10 (SEQ ID NO:13), P00199_D08 (SEQ ID NO:15), P00203_D04 (SEQ ID NO:17), P00203_E06 (SEQ ID NO:19), P00209_F06 (SEQ ID NO:21), P00219_D02 (SEQ ID NO:23), P00219_F06 (SEQ ID NO:25), P00220_H05 (SEQ ID NO:27), P00222_G03 (SEQ ID NO:29), P00225_C01 (SEQ ID NO:32), P00227_D11 (SEQ ID NO:34), P00228_F03 (SEQ ID NO:36), P00233_H08 (SEQ ID NO:38), P00235_G08 (SEQ ID NO:40), P00239_C11 (SEQ ID NO:42), P00240_E05 (SEQ ID NO:45), P00247_A04 (SEQ ID NO:50), P00248_B04 (SEQ ID NO:52), P00249_F09 (SEQ ID NO:54), P00258_A10 (SEQ ID NO:56), P00262_C10 (SEQ ID NO:58), P00269_H08 (SEQ ID NO:62), P00628_H02 (SEQ ID NO:66), P00629_C08 (SEQ ID NO:68), P00641_G11 (SEQ ID NO:71), P00648_E12 (SEQ ID NO:73), P00697_C03 (SEQ ID NO:75), and other mammalian homologues and variants of such factor, as well as polynucleotides encoding them. The invention further concerns methods and means for producing such factors and their use in the diagnosis and treatment of various cardiac, renal or inflammatory diseases.
摘要翻译：本发明涉及由克隆P00184_D11（SEQ ID NO：1），P00185_D11（SEQ ID NO：3），P00188_D12（SEQ ID NO：5），P00188_E01（SEQ ID NO：7），P00194_G01（SEQ ID NO： P00194_G05（SEQ ID NO：11），P00194_H10（SEQ ID NO：13），P00199_D08（SEQ ID NO：15），P00203_D04（SEQ ID NO：17），P00203_E06（SEQ ID NO：19），P00209_F06 （SEQ ID NO：21），P00219_D02（SEQ ID NO：23），P00219_F06（SEQ ID NO：25），P00220_H05（SEQ ID NO：27），P00222_G03（SEQ ID NO：29），P00225_C01 P00227_D11（SEQ ID NO：34），P00228_F03（SEQ ID NO：36），P00233_H08（SEQ ID NO：38），P00235_G08（SEQ ID NO：40），P00239_C11（SEQ ID NO：42），P00240_E05 P00248_A04（SEQ ID NO：50），P00248_B04（SEQ ID NO：52），P00249_F09（SEQ ID NO：54），P00258_A10（SEQ ID NO：56），P00262_C10（SEQ ID NO：），P00269_H08（SEQ ID NO：62），P00628_H02（SEQ ID NO：66），P00629_C08（SEQ ID NO：68），P00641_G11（SEQ ID NO：71），P00648_E12（SEQ ID NO：73），P00697_C03 SEQ ID NO：75）和其他哺乳动物同系物及其变体因子，以及编码它们的多核苷酸。本发明还涉及用于产生这些因素及其在诊断和治疗各种心脏，肾脏或炎症疾病中的用途的方法和手段。

2. 发明授权

US06342495B1 Agonists and antagonists of peripheral-type benzodiazepine receptors 有权
标题翻译：外周型苯二氮类受体的激动剂和拮抗剂
公开(公告)号：US06342495B1
公开(公告)日：2002-01-29
申请号：US09461780
申请日：1999-12-15
申请人： Alison Joly , George F. Schreiner , Lawrence W. Stanton , R. Tyler White
发明人： Alison Joly , George F. Schreiner , Lawrence W. Stanton , R. Tyler White
IPC分类号： A61K3155
CPC分类号： C12Q1/6883 , C12Q2600/158
摘要： The invention concerns the use of agonists and antagonists of peripheral-type benzodiazcpine receptors (PTBR) in the diagnosis and treatment of cardiac hypertrophy and other circulatory conditions. The invention specifically concerns the use of PTBR antagonists in the prevention or treatment of decompensated cardiac hypertrophy and, eventually, heart failure. The invention also concerns the use of PTBR agonists in the management of conditions calling for increased blood flow or cardiac output, including injury or functional compromise of the heart, increased demand for physical exercise, or an acquired or inherited predisposition to cardiac contractile disfunction. Pharmaceutical compositions for the treatment of such conditions and screening methods to identify PTBR agonists and antagonists are also included.
摘要翻译：本发明涉及外周型苯并二氮对受体（PTBR）的激动剂和拮抗剂在心脏肥大和其它循环状况的诊断和治疗中的应用。本发明具体涉及使用PTBR拮抗剂来预防或治疗失代偿性心脏肥大，最终导致心力衰竭。本发明还涉及PTBR激动剂在管理呼吸增加的血流量或心输出量的情况下的应用，包括对心脏的损伤或功能损害，对体育运动的增加的需求，或心脏收缩功能障碍的获得或遗传倾向。还包括用于治疗这些病症的药物组合物和鉴定PTBR激动剂和拮抗剂的筛选方法。

3. 发明授权

US06709855B1 Methods for detection and use of differentially expressed genes in disease states 有权
标题翻译：在疾病状态下检测和使用差异表达基因的方法
公开(公告)号：US06709855B1
公开(公告)日：2004-03-23
申请号：US09461912
申请日：1999-12-15
申请人： Lawrence W. Stanton , R. Tyler White , Deborah L. Damm , John A. Lewicki , Alison Joly , George F. Schreiner
发明人： Lawrence W. Stanton , R. Tyler White , Deborah L. Damm , John A. Lewicki , Alison Joly , George F. Schreiner
IPC分类号： C12M134
CPC分类号： C12Q1/6876 , C12Q1/6837 , C12Q2600/158
摘要： The present invention relates to methods and compositions for the detection, diagnosis, prevention and treatment of a disease, specifically cardiac, kidney or inflammatory disease, and related disorders. The present invention also relates to compositions and methods useful in the diagnosis, prevention and therapeutic treatment of a disease, specifically cardiac, kidney or inflammatory disease. Specifically, methods and compositions are provided for the diagnostic evaluation and prognosis of conditions involving a disease, specifically cardiac, kidney or inflammatory disease, for the identification of subjects exhibiting a predisposition to such conditions, for modulating the effect of these differentially expressed genes, for monitoring patients undergoing clinical evaluation for the prevention and treatment of a disease, specifically cardiac, kidney or inflammatory disease, and its disorders, and for monitoring the efficacy of compounds used in clinical trials.
摘要翻译：本发明涉及用于检测，诊断，预防和治疗疾病，特别是心脏，肾脏或炎症性疾病以及相关疾病的方法和组合物。本发明还涉及用于诊断，预防和治疗疾病，特别是心脏，肾脏或炎性疾病的组合物和方法。具体地，提供方法和组合物用于诊断评估和预后涉及疾病，特别是心脏，肾脏或炎性疾病的疾病，用于鉴定表现出对这些病症倾向的受试者，用于调节这些差异表达基因的作用，用于监测接受临床评估的患者，用于预防和治疗疾病，特别是心脏，肾脏或炎症疾病及其疾病，并监测临床试验中使用的化合物的功效。

4. 发明授权

US06686354B2 Agonists and antagonists of peripheral-type benzodiazepine receptors 有权
标题翻译：外周型苯二氮类受体的激动剂和拮抗剂
公开(公告)号：US06686354B2
公开(公告)日：2004-02-03
申请号：US10033189
申请日：2001-12-27
申请人： Alison Joly , George F. Schreiner , Lawrence W. Stanton , R. Tyler White
发明人： Alison Joly , George F. Schreiner , Lawrence W. Stanton , R. Tyler White
IPC分类号： A61K3155
CPC分类号： C12Q1/6883 , C12Q2600/158
摘要： The invention concerns the use of agonists and antagonists of peripheral-type benzodiazepine receptors (PTBR) in the diagnosis and treatment of cardiac hypertrophy and other circulatory conditions. The invention specifically concerns the use of PTBR antagonists in the prevention or treatment of decompensated cardiac hypertrophy and, eventually, heart failure. The invention also concerns the use of PTBR agonists in the management of conditions calling for increased blood flow or cardiac output, including injury or functional compromise of the heart, increased demand for physical exercise, or an acquired or inherited predisposition to cardiac contractile disfunction. Pharmaceutical compositions for the treatment of such conditions and screening methods to identify PTBR agonists and antagonists are also included.
摘要翻译：本发明涉及外周型苯二氮卓受体（PTBR）的激动剂和拮抗剂在心脏肥大和其他循环状况的诊断和治疗中的应用。本发明具体涉及使用PTBR拮抗剂来预防或治疗失代偿性心脏肥大，最终导致心力衰竭。本发明还涉及PTBR激动剂在管理呼吸增加的血流量或心输出量的情况下的应用，包括对心脏的损伤或功能损害，对体育运动的增加的需求，或心脏收缩功能障碍的获得或遗传倾向。还包括用于治疗这些病症的药物组合物和鉴定PTBR激动剂和拮抗剂的筛选方法。

5. 发明授权

US07202344B2 Secreted factors 有权
标题翻译：分散因素
公开(公告)号：US07202344B2
公开(公告)日：2007-04-10
申请号：US10959440
申请日：2004-10-05
申请人： Lawrence W. Stanton , R. Tyler White
发明人： Lawrence W. Stanton , R. Tyler White
IPC分类号： C07K16/00 , C07K16/18 , G01N33/53 , G01N33/563
CPC分类号： C07K14/47
摘要： The invention concerns new secreted factors encoded by clones P00184_D11 (SEQ ID NO: 1), P00185_D11 (SEQ ID NO: 3), P00188_D12 (SEQ ID NO: 5), P00188_E01 (SEQ ID NO: 7), P00194_G01 (SEQ ID NO: 9), P00194_G05 (SEQ ID NO: 11), P00194_H10 (SEQ ID NO: 13), P00199_D08 (SEQ ID NO: 15), P00203_D04 (SEQ ID NO: 17), P00203_E06 (SEQ ID NO: 19), P00209_F06 (SEQ ID NO: 21), P00219_D02 (SEQ ID NO: 23), P00219_F06 (SEQ ID NO: 25), P00220_H05 (SEQ ID NO: 27), P00222_G03 (SEQ ID NO: 29), P00225_C01 (SEQ ID NO: 32), P00227_D11 (SEQ ID NO: 34), P00228_F03 (SEQ ID NO: 36), P00233_H08 (SEQ ID NO: 38), P00235_G08 (SEQ ID NO: 40), P00239_C11 (SEQ ID NO: 42), P00240_E05 (SEQ ID NO: 45), P00247_A04 (SEQ ID NO: 50), P00248_B04 (SEQ ID NO: 52), P00249_F09 (SEQ ID NO: 54), P00258_A10 (SEQ ID NO: 56), P00262_C10 (SEQ ID NO: 58), P00269_H08 (SEQ ID NO: 62), P00628_H02 (SEQ ID NO: 66), P00629_C08 (SEQ ID NO: 68), P00641_G11 (SEQ ID NO: 71), P00648_E12 (SEQ ID NO: 73), P00697_C03 (SEQ ID NO: 75), and other mammalian homologues and variants of such factor, as well as polynucleotides encoding them. The invention further concerns methods and means for producing such factors and their use in the diagnosis and treatment of various cardiac, renal or inflammatory diseases.
摘要翻译：本发明涉及由克隆P00184_D11（SEQ ID NO：1），P00185_D11（SEQ ID NO：3），P00188_D12（SEQ ID NO：5），P00188_E01（SEQ ID NO：7），P00194_G01（SEQ ID NO： P00194_G05（SEQ ID NO：11），P00194_H10（SEQ ID NO：13），P00199_D08（SEQ ID NO：15），P00203_D04（SEQ ID NO：17），P00203_E06（SEQ ID NO：19），P00209_F06 （SEQ ID NO：21），P00219_D02（SEQ ID NO：23），P00219_F06（SEQ ID NO：25），P00220_H05（SEQ ID NO：27），P00222_G03（SEQ ID NO：29），P00225_C01 P00227_D11（SEQ ID NO：34），P00228_F03（SEQ ID NO：36），P00233_H08（SEQ ID NO：38），P00235_G08（SEQ ID NO：40），P00239_C11（SEQ ID NO：42），P00240_E05 P00248_A04（SEQ ID NO：50），P00248_B04（SEQ ID NO：52），P00249_F09（SEQ ID NO：54），P00258_A10（SEQ ID NO：56），P00262_C10（SEQ ID NO：），P00269_H08（SEQ ID NO：62），P00628_H02（SEQ ID NO：66），P00629_C08（SEQ ID NO：68），P00641_G11（SEQ ID NO：71），P00648_E12（SEQ ID NO：73），P00697_C03 ID NO：75）和其他哺乳动物这些因子的同系物和变体，以及编码它们的多核苷酸。本发明还涉及用于产生这些因素及其在诊断和治疗各种心脏，肾脏或炎症疾病中的用途的方法和手段。

6. 发明授权

US5962266A Protease inhibitor peptides 失效
公开(公告)号：US5962266A
公开(公告)日：1999-10-05
申请号：US829876
申请日：1997-04-02
申请人： R. Tyler White , Deborah Damm , David D. Lesikar , Kathleen McFadden , Brett L. Garrick
发明人： R. Tyler White , Deborah Damm , David D. Lesikar , Kathleen McFadden , Brett L. Garrick
IPC分类号： A61K38/00 , A61P7/00 , C07K14/81 , C12P21/06 , C07H21/02 , C12N1/20
CPC分类号： C07K14/8114 , C07K14/81 , A61K38/00 , C07K2319/02
摘要： Analogues of the Kunitz Protease Inhibitor (KPI) domain of amyloid precursor protein bind to and inhibit activity of serine proteases, including kallikrein, plasmin and coagulation factors such as factors VIIa, IXa, Xa, XIa, and XIIa. Pharmaceutical compositions containing the KPI analogues, along with methods for using such compositions, are useful for ameliorating and treating clinical conditions associated with increased serine protease activity, such as blood loss related to cardiopulmonary bypass surgery. Nucleic acid sequences encoding these analogues and systems for expression of the peptides of the invention are provided.

7. 发明授权

US06906033B2 Protease inhibitor peptides 失效
标题翻译：蛋白酶抑制剂肽
公开(公告)号：US06906033B2
公开(公告)日：2005-06-14
申请号：US10076604
申请日：2002-02-19
申请人： R. Tyler White , Deborah Damm , David D. Lesikar , Kathleen McFadden , Brett L. Garrick
发明人： R. Tyler White , Deborah Damm , David D. Lesikar , Kathleen McFadden , Brett L. Garrick
IPC分类号： A61K38/00 , A61P7/00 , C07K14/81 , A61K38/16 , C07H21/04
CPC分类号： C07K14/8114 , A61K38/00 , C07K14/81 , C07K2319/02
摘要： Analogues of the Kunitz Protease Inhibitor (KPI) domain of amyloid precursor protein bind to and inhibit activity of serine proteases, including kallikrein, plasmin and coagulation factors such as factors VIIa, IXa, Xa, XIa, and XIIa. Pharmaceutical compositions containing the KPI analogues, along with methods for using such compositions, are useful for ameliorating and treating clinical conditions associated with increased serine protease activity, such as blood loss related to cardiopulmonary bypass surgery. Nucleic acid sequences encoding these analogues and systems for expression of the peptides of the invention are provided.
摘要翻译：淀粉样蛋白前体蛋白的Kunitz蛋白酶抑制剂（KPI）结构域的类似物结合并抑制丝氨酸蛋白酶的活性，包括激肽释放酶，纤溶酶和凝血因子如因子VIIa，IXa，Xa，XIa和XIIa。包含KPI类似物的药物组合物以及使用这些组合物的方法可用于改善和治疗与丝氨酸蛋白酶活性增加相关的临床病症，例如与体外循环手术相关的失血。提供了编码这些用于表达本发明的肽的类似物和系统的核酸序列。

8. 发明授权

US06613890B2 Protease inhibitor peptides 有权
公开(公告)号：US06613890B2
公开(公告)日：2003-09-02
申请号：US09234873
申请日：1999-01-21
申请人： R. Tyler White , Deborah Damm , David D. Lesikar , Kathleen McFadden , Brett L. Garrick
发明人： R. Tyler White , Deborah Damm , David D. Lesikar , Kathleen McFadden , Brett L. Garrick
IPC分类号： C07H2104
CPC分类号： C07K14/8114 , A61K38/00 , C07K14/81 , C07K2319/02
摘要： Analogues of the Kunitz Protease Inhibitor (KPI) domain of amyloid precursor protein bind to and inhibit activity of serine proteases, including kallikrein, plasmin and coagulation factors such as factors VIIa, IXa, Xa, XIa, and XIIa. Pharmaceutical compositions containing the KPI analogues, along with methods for using such compositions, are useful for ameliorating and treating clinical conditions associated with increased serine protease activity, such as blood loss related to cardiopulmonary bypass surgery. Nucleic acid sequences encoding these analogues and systems for expression of the peptides of the invention are provided.

9. 发明授权

US06380183B1 Treatment of diseases involving cyst formation 有权
标题翻译：治疗涉及囊肿形成的疾病
公开(公告)号：US06380183B1
公开(公告)日：2002-04-30
申请号：US09461910
申请日：1999-12-15
申请人： George F. Schreiner , Alison Joly , Lawrence W. Stanton , R. Tyler White
发明人： George F. Schreiner , Alison Joly , Lawrence W. Stanton , R. Tyler White
IPC分类号： A61K3155
CPC分类号： A61K45/06 , A61K31/5513 , A61K38/212 , G01N33/948 , A61K2300/00
摘要： The invention concerns the use of ligands of peripheral-type benzodiazepine receptors (PTBR) in the diagnosis and treatment of diseases involving cyst formation and in particular polycystic kidney disease. The invention further concerns the treatment of hypertension accompanying polycystic kidney disease, and pharmaceutical compositions and articles of manufacture for the treatment or diagnosis of the target disease or condition.
摘要翻译：本发明涉及外周型苯二氮卓受体（PTBR）的配体在诊断和治疗涉及囊肿形成，特别是多囊肾病的疾病中的用途。本发明还涉及治疗伴随多囊肾病的高血压，以及用于治疗或诊断目标疾病或病症的药物组合物和制品。

10. 发明授权

US06376648B2 Protease inhibitor peptides 有权
标题翻译：蛋白酶抑制剂肽
公开(公告)号：US06376648B2
公开(公告)日：2002-04-23
申请号：US09234874
申请日：1999-01-21
申请人： R. Tyler White , Deborah Damm , David D. Lesikar , Kathleen McFadden , Brett L. Garrick
发明人： R. Tyler White , Deborah Damm , David D. Lesikar , Kathleen McFadden , Brett L. Garrick
IPC分类号： C07K1481
CPC分类号： C07K14/8114 , A61K38/00 , C07K14/81 , C07K2319/02
摘要： Analogues of the Kunitz Protease Inhibitor (KPI) domain of amyloid precursor protein bind to and inhibit activity of serine proteases, including kallikrein, plasmin and coagulation factors such as factors VIIa, IXa, Xa, XIa, and XIIa. Pharmaceutical compositions containing the KPI analogues, along with methods for using such compositions, are useful for ameliorating and treating clinical conditions associated with increased serine protease activity, such as blood loss related to cardiopulmonary bypass surgery. Nucleic acid sequences encoding these analogues and systems for expression of the peptides of the invention are provided.
摘要翻译：淀粉样蛋白前体蛋白的Kunitz蛋白酶抑制剂（KPI）结构域的类似物结合并抑制丝氨酸蛋白酶的活性，包括激肽释放酶，纤溶酶和凝血因子如因子VIIa，IXa，Xa，XIa和XIIa。包含KPI类似物的药物组合物以及使用这些组合物的方法可用于改善和治疗与丝氨酸蛋白酶活性增加相关的临床病症，例如与体外循环手术相关的失血。提供了编码这些用于表达本发明的肽的类似物和系统的核酸序列。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式